EMPLICITI + Pd Dosing
EMPLICITI is administered as a component of the EPd regimen1
Treatment should continue until disease progression or unacceptable toxicity
EPd DOSING SCHEDULE
EPd, EMPLICITI + pomalidomide + dexamethasone; Pd, pomalidomide + dexamethasone.
*
In a 28-day cycle, days 23 through 28 are rest periods, during which no active therapy is given.
†
Oral dexamethasone (28 mg or 8 mg) should be taken between 3 and 24 hours before EMPLICITI infusion.
*
In a 28-day cycle, days 23 through 28 are rest periods, during which no active therapy is given.
†
Oral dexamethasone (8 mg, 20 mg, 28 mg, or 40 mg) should be taken between 3 and 24 hours before EMPLICITI infusion.
†
On days that EMPLICITI is not administered, but a dose of dexamethasone is scheduled, dexamethasone 20 mg (patients ≤75 years old) or 40 mg (patients >75 years old) should be given orally.
Patients must be premedicated before each dose of EMPLICITI
PRETREATMENT ON DAYS THAT EMPLICITI IS ADMINISTERED
If no infusion reactions develop, the infusion rate may be increased in a stepwise fashion as shown below:
INFUSION RATE FOR EMPLICITI†
†
The maximum infusion rate should not exceed 5 mL/min.
The presence and severity of infusion reaction may lengthen the infusion time for EMPLICITI.
Dosing and Ordering Guide
A reference guide for dosing, ordering, and product returns, plus support services for you and your patients.
SELECTED IMPORTANT SAFETY INFORMATION
Pregnancy/Females and Males of Reproductive Potential
- There are no available data on EMPLICITI use in pregnant women to inform a drug-associated risk of major defects and miscarriage.
- There is a risk of fetal harm, including severe life-threatening human birth defects, associated with pomalidomide, and it is contraindicated for use in pregnancy. Refer to the pomalidomide full prescribing information for requirements regarding contraception and the prohibitions against blood and/or sperm donation due to presence and transmission in blood and/or semen and for additional information.
Please see additional Important Safety Information below.